Allero Therapeutics is a Dutch, venture-backed, biopharmaceutical company that develops next generation immunotherapies for immune mediated disorders. Our goal is to develop novel targeted treatments that induce long-lasting antigen-specific tolerance. Our proprietary SOMIT (Specific Oromucosal Immunotherapy) technology combines a tolerance-inducing agent with novel oral patch mediated targeted delivery of specific antigens to the oral mucosa immune privilege.